Therapeutic approach to the patient with irritable bowel syndrome

American Journal of Medicine

Volumn 107, Issue 5 SUPPL. 1, 1999, Pages 27-32

  Camilleri, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; AMITRIPTYLINE; ANTIDIARRHEAL AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETROPIUM; CODEINE; COLESTYRAMINE; DESIPRAMINE; DICYCLOVERINE; DIPHENOXYLATE; FLUPHENAZINE; ISPAGULA; LOPERAMIDE; MEBEVERINE; NORTRIPTYLINE; OPIATE; OTILONIUM BROMIDE; PEPPERMINT OIL; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TRIMEBUTINE; TRIMIPRAMINE;

ABDOMINAL PAIN; CONSTIPATION; DEPRESSION; DIARRHEA; DIET; DRUG EFFICACY; HUMAN; INTESTINE CONTRACTION; IRRITABLE COLON; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW;

EID: 0032693909     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00279-X     Document Type: Article

References (54)

1. Klein K.B. Controlled treatment trials in the irritable bowel syndrome. Gastroenterology. 95:1988;232-241.
2. Drossman D.A., Whitehead W.E., Camilleri M. Irritable bowel syndrome a technical review for practice guideline development . Gastroenterology. 112:1997;2120-2137.
3. Poynard T., Naveau S., Mory B., Chaput J.C. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 8:1994;499-510.
4. Camilleri M., Prather C.M. The irritable bowel syndrome mechanisms and a practical approach to management . Ann Intern Med. 116:1992;1001-1008.
5. Camilleri M., Choi M.G. Irritable bowel syndrome. Aliment Pharmacol Ther. 11:1997;3-15.
6. Mayer E.A. Emerging disease model for functional gastrointestinal disorders. Am J Med. 107:(4A):1999;5S-11S.
7. Cann P.A., Read N.W., Holdsworth C.D. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut. 25:1984;168-173.
8. Jarrett M., Heitkemper M.M., Bond E.F., Georges J. Comparison of diet composition in women with and without functional bowel disorder. Gastroenterol Nursing. 6:1994;253.
9. Distrutti E., Azpiroz F., Soldevilla A., Malagelada J.-R. Gastric wall tension determines perception of gastric distention. Gastroenterology. 116:1999;1035-1042.
10. 2-adrenergic agents in humans. Gastroenterology. 116:1999;573-585.
11. Malcolm A., Phillips S.F., Camilleri M., Hanson R.B. Pharmacological modulation of rectal tone alters perception of distention in humans. Am J Gastroenterol. 92:1997;2073-2079.
12. Mueller-Lissner S.A. Effect of wheat bran on weight of stool and gastrointestinal transit time a meta-analysis . BMJ. 296:1988;615-617.
13. Cook I.J., Irvine E.J., Campbell D., Shannon S., Reddy S.N., Collins S.M. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. Gastroenterology. 98:1990;66-72.
14. Snook J., Shepherd H.A. Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 8:1994;511-514.
15. Francis C.Y., Whorwell P.J. Bran and irritable bowel syndrome time for reappraisal . Lancet. 344:1994;39-40.
16. Whitehead W.E., Holtkotter B., Enck P., et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology. 98:1990;1187-1192.
17. Haderstorfer B., Psycholgin D., Whitehead W.E., Schuster M.M. Intestinal gas production from bacterial fermentation of undigested carbohydrate in irritable bowel syndrome. Am J Gastroenterol. 84:1989;375-378.
18. Lasser R.B., Levitt M.D. The role of intestinal gas in functional abdominal pain. N Engl J Med. 293:1975;524-526.
19. Hebden JM, Blackshaw E, Perkins AC, D'Amato M, Spiller RC. Impaired ascending colon clearance in response to rapid small bowel transit in bloated irritable bowel syndrome: bran exaggerates the problems. Gastroenterology. 1999;116:A1004. Abstract.
20. Voderholzer WA, Schatke W, Muhldorfer BE, Klauser AG, Birkner B, Muller-Lissner SA. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol. 1997;92:95-98.
21. Lucey M.R., Clark M.L., Lowndes J., Dawson A.M. Is bran efficacious in irritable bowel syndrome? A double-blind, placebo-controlled crossover study. Gut. 28:1987;221-225.
22. Feldman W., McGrath P., Hodgson C., Ritter H., Shipman R.T. The use of dietary fiber in the management of simple, childhood, idiopathic, recurrent abdominal pain results in a prospective, double-blind, randomized, controlled trial . Am J Dis Child. 138:1985;1216-1218.
23. Hillman L.C., Stace N.H., Pomare E.W. Irritable bowel patients and their long-term response to a high fiber diet. Am J Gastroenterol. 79:1984;1-7.
24. Vassallo M.J., Camilleri M., Phillips S.F., Steadman C.J., Hanson R.B., Haddad A.C. Colonic tone and motility in patients with irritable bowel syndrome. Mayo Clin Proc. 67:1992;725-731.
25. Cann P.A., Read N.W., Holdsworth C.D., Barends D. Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci. 29:1984;239-247.
26. Read M., Read N.W., Barber D.C., Duthie H.L. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci. 27:1982;807-814.
27. Rattan S., Culver P.J. Influence of loperamide on the internal anal sphincter in the opossum. Gastroenterology. 93:1987;121-128.
28. Musial F., Enck P., Kalveram K.T., Erckenbrecht J.F. The effect of loperamide on anorectal function in normal healthy men. J Clin Gastroenterol. 15:1992;321-324.
29. Hallgren T., Fasth S., Delbro D.S., Nordgren S., Oresland T., Hulten L. Loperamide improves anal sphincter function and continence after restorative proctocolectomy. Dig Dis Sci. 39:1994;2612-2618.
30. Sun W.M., Read N.W., Verlinden M. Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol. 32:1997;34-38.
31. Thaysen E.H., Pedersen L. Idiopathic bile salt catharsis. Gut. 17:1976;965-970.
32. Luman W., Williams A.J., Merrick M.V., Eastwood M.A. Idiopathic bile acid malabsorption long-term outcome . Eur J Gastroenterol Hepatol. 7:1995;641-645.
33. Brydon W.G., Nyhlin H., Eastwood M.A., Merrick M.V. Serum 7alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol. 8:1996;117-123.
34. 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut. 28:1987;970-975.
35. Pittler M.H., Ernst E. Peppermint oil for irritable bowel syndrome a critical review and metaanalysis . Am J Gastroenterol. 93:1998;1131-1135.
36. Clouse R.E. Antidepressants for functional gastrointestinal syndromes. Dig Dis Sci. 39:1994;2352-2363.
37. Heefner J.D., Wilder R.M., Wilson J.D. Irritable colon and depression. Psychosomatics. 19:1978;540-547.
38. Hislop I.G. Psychological significance of the irritable colon syndrome. Gut. 12:1971;452-457.
39. Lancaster-Smith M.J., Prout B.J., Pinto T., Anderson J.A., Schiff A.A. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity. Acta Psychiatr Scand. 66:1982;33-41.
40. Onghena P., Houdenhove B.V. Antidepressant-induced analgesia in chronic non-malignant pain a meta-analysis of 39 placebo-controlled studies . Pain. 49:1992;205-219.
41. Gorelick A.B., Koshy S.S., Hooper F.G., Bennett T.C., Chey W.D., Hasler W.L. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol. 275:1998;G460-G466.
42. American Gastroenterological Association Medical Position Statement. Irritable bowel syndrome. Gastroenterology. 1997;112:2118-2119.
43. Myren J., Groth H., Larssen S.E., Larsen S. The effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol. 17:1982;871-875.
44. Myren J., Lovland B., Larssen S.-E., Larsen S. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol. 19:1984;835-843.
45. Greenbaum D.S., Mayle J.E., Vanegeren L.E., et al. The effects of desipramine on IBS compared with atropine and placebo. Dig Dis Sci. 32:1987;257-266.
46. Ritchie J.A., Truelove S.C. Comparison of various treatments for irritable bowel syndrome. BMJ. 281:1980;1317-1319.
47. Gram L.F. Fluoxetine. N Engl J Med. 20:1994;1354-1361.
48. Whorwell P.J., Prior A., Faragher E.B. Hypnotherapy in irritable bowel syndrome. Lancet. ii:1984;1232-1234.
49. Svedlund J. Psychotherapy in irritable bowel syndrome a controlled outcome study . Acta Psychiatr Scand. 67:1983;1-86.
50. Guthrie E., Creed F., Dawson D., Tomerson B. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology. 100:1991;450-457.
51. Whorwell P.J. Hypnotherapy in the irritable bowel syndrome. Stress Med. 3:1987;5-7.
52. Talley N.J., Owen B.K., Boyce P., Paterson K. Psychological treatments for irritable bowel syndrome a critique of controlled treatment trials . Am J Gastroenterol. 91:1996;277-283.
53. Dapoigny M., Abitbol J.L., Fraitag B. Efficacy of peripheral kappa agonist, fedotozine, vs. placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci. 40:1995;2244-2249.
54. 3-receptor antagonist. Aliment Pharmacol Ther 1999;13:610-620.